SGCA
PACB icon

Steel Grove Capital Advisors’s Pacific Biosciences PACB Stock Holding History

Steel Grove Capital Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-11,000
Closed -$40K – 208
2015
Q3 		$40K Hold
11,000
– – 0.01% 188
2015
Q2 		$63K Hold
11,000
– – 0.01% 186
2015
Q1 		$64K Buy
+11,000
New +$75.8K 0.01% 166

Other funds holding PACB

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Steel Grove Capital Advisors's PACB Position: Q4 2015 in Review

Steel Grove Capital Advisors sold out of Pacific Biosciences (PACB) in Q4 2015, closing a stake of 11,000 shares — an estimated $40K sold.

Steel Grove Capital Advisors first reported a position in PACB in Q1 2015 and held it in 3 quarters. The position peaked at $64K in Q1 2015. 119 funds tracked by Wall St. Rank hold PACB as of Q4 2015.

  • Steel Grove Capital Advisors reported no remaining Pacific Biosciences position as of Q4 2015 after selling out during the quarter.
  • Steel Grove Capital Advisors sold 11,000 Pacific Biosciences shares in Q4 2015, an estimated $40K.
  • Steel Grove Capital Advisors first reported a position in Pacific Biosciences in Q1 2015 and held it in 3 quarters.
  • Steel Grove Capital Advisors's Pacific Biosciences position peaked at $64K in Q1 2015.
  • 119 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2015.

Based on Steel Grove Capital Advisors's 13F filing for Q4 2015, filed 10 Feb 2016.